Published date: 17 January 2022

This notice was replaced on 17 January 2022

This notice does not contain the most up-to-date information about this procurement. The most recent notice is:

Awarded contract (published 17 January 2022)

Awarded contract - This means that the contract has been awarded to a supplier.


Contract summary

Industry

  • Pharmaceutical products - 33600000

Location of contract

SW1H 0EU

Value of contract

£1

Procurement reference

CF-0581200D0O000000rwimUAA1

Published date

17 January 2022

Closing date

19 December 2021

Closing time

11pm

Contract start date

20 December 2021

Contract end date

31 December 2022

Contract type

Supply contract

Procedure type

Negotiated procedure without prior publication (above threshold)

The opportunity was not advertised, because for example only one supplier is capable of delivering the requirement, or due to extreme urgency brought about by unforeseen events.

This procedure can be used for procurements above the relevant contract value threshold.

Contract is suitable for SMEs?

No

Contract is suitable for VCSEs?

No

Description

Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative.
This agreement is for the procurement of 2,500,000 units of PF-07321332/ritonavir. It is one of the first oral and direct-acting antiviral drugs globally and is part of the UK's multi-layered approach to COVID-19.

More information

Links

Award information

Awarded date

20 December 2021

Contract start date

20 December 2021

Contract end date

31 December 2022

Total value of contract

£1

This contract was awarded to 1 supplier.

Pfizer Limited

Address

Walton Oaks, Dorking Road KT20 7NS

Reference

None

About the buyer

Contact name

Amy Watkins

Address

39 Victoria Street
London
SW1H 0EU
GB

Email

AntiviralsTaskforce@dhsc.gov.uk